Value Investor
Start free

LENZ Therapeutics

LENZ on Nasdaq. Market value $113m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

Nothing stands out yet.

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
-47.1%low

For every $100 of what the whole company costs, it produced $-47.10 of spare cash last year. A savings account pays about $4.

Price to profit
n/a

The filings do not give us enough to work this out.

Return on capital
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

Five years of cash, in billions

-0.1
-0.1
20242025
Revenue
$0$19m
Operating margin
n/a-477.5%
Debt to equity
n/an/a
Shares outstanding
0.06bn0.03bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting checksSkipped: company is not yet profitable
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesYes, 53% fewer since 2024

Dates

Next results (estimated)
n/a
Last annual report (10-K)
24 March 2026
Next quarterly (estimated, 10-Q)
10 November 2026

Who owns it

None of the long-term investors we follow own it. 144 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

8 investors own more than 5%.

  • at least 13.6%−1.5 pts
    (filed with 3 related holders)
    Since 5 November 2025
  • BlackRock, Inc.
    Passive investor
    5.8%+0.9 pts
    Since 31 March 2026
  • FMR LLC
    Passive investor
    at least 5.7%−6.1 pts
    (filed with 1 related holder)
    Since 31 August 2026
  • at least 5.1%
    (filed with 2 related holders)
    Since 23 June 2026
  • Squarepoint Ops LLC
    Passive investor
    at least 5.1%
    (filed with 5 related holders)
    Since 1 April 2026
  • Steven A. Cohen
    Passive investor
    at least 4.8%
    (filed with 5 related holders)
    Since 30 September 2025
  • at least 3.8%−1.4 pts
    (filed with 3 related holders)
    Since 30 September 2025
  • Versant Venture Capital VI, L.P.
    Passive investor
    at least 3.4%−0.7 pts
    (filed with 8 related holders)
    Since 5 November 2025
  • Ridgeback Capital Investments LLC
    Passive investor
    Sold down below 5%
    Since 31 December 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 4 insiders bought $654,873 of shares on the open market. 1 sold $261,046, $261,046 of it under preset trading plans.

  • George Jeffrey P.
    Director
    Bought
    Date
    27 March 2026
    Shares
    5,592
    Price
    $8.92
    Value
    $49,881
  • Schimmelpennink Evert B.
    President, CEO and Secretary, Director
    Bought
    Date
    27 March 2026
    Shares
    28,089
    Price
    $8.95
    Value
    $251,397
  • Chevallard Daniel R.
    Chief Financial Officer
    Bought
    Date
    27 March 2026
    Shares
    7,500
    Price
    $8.57
    Value
    $64,275
  • Olsson Shawn
    Chief Commercial Officer
    Sold
    under a preset trading plan
    Date
    17 November 2025
    Shares
    10,000
    Price
    $26.10
    Value
    $261,046
  • MCCOLLUM JAMES W
    Director
    Bought
    Date
    7 November 2025
    Shares
    10,500
    Price
    $22.79
    Value
    $239,295
  • Chevallard Daniel R.
    Chief Financial Officer
    Bought
    Date
    7 November 2025
    Shares
    2,198
    Price
    $22.76
    Value
    $50,025

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 24 Mar 2026, plus the 10-Q filed 11 Aug 2026 and 4 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.